Immune Tolerance Induction by Anti-CD4 Monoclonal Antibody in Experimental Autoimmune Anterior Uveitis.
- Author:
Hyeong Gon YU
1
;
Dong Sup LEE
;
Hum CHUNG
Author Information
1. Department of Ophthalmology, Seoul National University, College of Medicine, Korea. chungh@snu.ac.kr
- Publication Type:Original Article
- Keywords:
Anti-CD4 antibody;
CD4+ T cell;
Experimental autoimmune anterior uveitis
- MeSH:
Animals;
Cell Death;
Immune Tolerance*;
Immunization;
Immunization, Secondary;
Inflammation;
Interleukin-10;
Rats;
T-Lymphocytes;
Uveitis;
Uveitis, Anterior*
- From:Journal of the Korean Ophthalmological Society
2003;44(10):2379-2386
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: To investigate the therapeutic potential of anti-CD4 antibody as an anti-inflammatory agent for the experimental autoimmune anterior uveitis. METHODS: Lewis rats were immunized with melanin-associated antigen and treated with anti-CD4 antibody for a week and then received secondary immunization with the same antigen at 8 weeks after primary immunization. The clinical grading of the uveitis and the effect of anti-CD4 on cell death and cytokine (IFN-gamma, IL-10) expression were followed. RESULTS: The cell death of CD4+ T cells was dependent on the dose of the antibody. The prevention of the primary uveitis paralleled the deletion of CD4+ T cells. The secondary uveitis was suppressed in the eyes treated early with lower doses (0.1, 1 mg/kg) of the antibody, even though mild degree of intraocular inflammation appeared in the primary uveitis in these groups. In the eyes treated with higher doses (10, 20 mg/kg), the severity of secondary uveitis was slightly reduced despite complete suppression of primary uveitis. IFN-gamma producing CD4+ T cells decreased and IL-10 producing CD4+ T cells increased after early anti-CD4 mAb treatment with a lower dose (1.0 mg/kg). CONCLUSIONS: These results show that anti-CD4 antibody treatment could be used in the future for the treatment of endogenous uveitis.
